These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29808092)

  • 1. The Efficacy and Safety of the Chinese Herbal Formula, JTTZ, for the Treatment of Type 2 Diabetes with Obesity and Hyperlipidemia: A Multicenter Randomized, Positive-Controlled, Open-Label Clinical Trial.
    Yu X; Xu L; Zhou Q; Wu S; Tian J; Piao C; Guo H; Zhang J; Li L; Wu S; Guo M; Hong Y; Pu W; Zhao X; Liu Y; Pang B; Peng Z; Wang S; Lian F; Tong X
    Int J Endocrinol; 2018; 2018():9519231. PubMed ID: 29808092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial.
    Tong X; Xu J; Lian F; Yu X; Zhao Y; Xu L; Zhang M; Zhao X; Shen J; Wu S; Pang X; Tian J; Zhang C; Zhou Q; Wang L; Pang B; Chen F; Peng Z; Wang J; Zhen Z; Fang C; Li M; Chen L; Zhao L
    mBio; 2018 May; 9(3):. PubMed ID: 29789365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Mechanism of the Jiangtang Tiaozhi Recipe in the Management of Type 2 Diabetes and Dyslipidaemia: A Clinical Trial Protocol.
    Wu H; Fang X; Jin D; Miao R; Wei J; Zhao T; Dai D; Liao J; Wang J; Lian F; Tian J
    Front Pharmacol; 2022; 13():827697. PubMed ID: 35185579
    [No Abstract]   [Full Text] [Related]  

  • 5. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
    Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
    Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of concentrated herbal extract granules, YH1, as an add-on medication in poorly controlled type 2 diabetes: A randomized, double-blind, placebo-controlled pilot trial.
    Huang YH; Chen ST; Liu FH; Hsieh SH; Lin CH; Liou MJ; Wang CC; Huang CH; Liu GH; Lin JR; Yang LY; Hsu TY; Lee MC; Huang CT; Wu YH
    PLoS One; 2019; 14(8):e0221199. PubMed ID: 31415655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
    Sahay RK; Giri R; Shembalkar JV; Gupta SK; Mohan B; Kurmi P; Kumar SR; Sawardekar VM; Mishra A; Murthy LS; Arya VV; Sonawane AR; Soni PN; Gofne SK; Karnawat SR; Rajurkar MN; Patel PM; Lakhwani LK; Mehta SC; Joglekar SJ
    Adv Ther; 2023 Jul; 40(7):3227-3246. PubMed ID: 37258803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.
    Li CJ; Li J; Zhang QM; Lv L; Chen R; Lv CF; Yu P; Yu DM
    Cardiovasc Diabetol; 2012 Nov; 11():142. PubMed ID: 23153177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [
    Zhang TT; Liu XM; Shi BY; Wang CJ; Mo ZH; Liu Y; Shan ZY; Yang WY; Li QM; Lyu XF; Yang JK; Xue YM; Zhu DL; Shi YQ; Huang Q; Zhou ZG; Wang Q; Ji QH; Li YB; Gao X; Lu JM; Zhang JQ; Guo XH
    Zhonghua Nei Ke Za Zhi; 2020 Dec; 59(12):960-967. PubMed ID: 33256337
    [No Abstract]   [Full Text] [Related]  

  • 15. Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open-label, randomized controlled trial (BEYOND VII).
    Ji L; Wan H; Wen B; Wang X; Wang J; Bian R; Pang W; Tian J; Wang Y; Bian F; Gao Z; Condoleon A; Feng W; Zhang X; Cui N
    Diabetes Obes Metab; 2020 May; 22(5):838-846. PubMed ID: 31944546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.
    Tamborlane WV; Laffel LM; Shehadeh N; Isganaitis E; Van Name M; Ratnayake J; Karlsson C; Norjavaara E
    Lancet Diabetes Endocrinol; 2022 May; 10(5):341-350. PubMed ID: 35378069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
    Terauchi Y; Usami M; Inoue T
    Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial.
    Haak T; Hanaire H; Ajjan R; Hermanns N; Riveline JP; Rayman G
    Diabetes Ther; 2017 Feb; 8(1):55-73. PubMed ID: 28000140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison Between Pioglitazone/Metformin Combination Therapy and Sitagliptin/Metformin Combination Therapy on the Efficacy in Chinese Type 2 Diabetic Adults Insufficiently Controlled with Metformin: Study Protocol of an Open-Label, Multicenter, Non-Inferiority Parallel-Group Randomized Controlled Trial.
    Zhang F; Tang L; Li J; Yan Z; Li J; Tong N
    Diabetes Metab Syndr Obes; 2021; 14():1243-1252. PubMed ID: 33776461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.